Post-earnings recap
Reported
Mon, May 4, 2026
EPS actual
$4.47
EPS est.
$3.69
EPS surprise
+21.20%
1-day move
+1.40%
Vertex Pharmaceuticals reported strong earnings with an EPS that exceeded expectations significantly, leading to a 1.4% increase in stock price. However, revenue figures were not disclosed, leaving some uncertainty. Investors may view the EPS beat positively, but the lack of revenue details and guidance could temper enthusiasm.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $4.47 | $4.29 | +21.20% |
| Revenue | N/A | $3.0B | N/A |
No transcript is on record, so the analysis is based solely on numerical results.
Vertex Pharmaceuticals Incorporated (VRTX) is a biotechnology company focused on developing and commercializing innovative therapies for serious diseases. With a market cap of $108 billion, it plays a significant role in the health care sector, particularly in the treatment of cystic fibrosis and other genetic disorders.
Last quarter
In the last quarter (Q4-2025), Vertex reported an EPS of $5.03, exceeding estimates by 14.21%. The stock reacted positively, gaining 0.82% the following day.
Management promises and guidance
EPS beat streak
8Q
EPS beat rate
100%
Avg EPS surprise
+16.95%
Avg 1-day reaction
+0.43%
Analysts expect Vertex to report strong earnings, with a consensus EPS of $4.29 and revenue of $3.0 billion. The company has a history of beating earnings expectations, which adds to investor optimism.
Bull case
If Vertex exceeds EPS and revenue estimates, it could signal robust demand for its products and a strong pipeline, leading to a positive stock reaction.
Bear case
If the company misses expectations or provides weak guidance, it could raise concerns about future growth and lead to a negative stock reaction.
Key metrics to watch
EPS
$4.29Earnings per share is a key indicator of the company's profitability and financial health.
Revenue
$3.0BRevenue figures provide insight into the company's sales performance and market demand for its products.
The print will turn on these.
Q1
Will the EPS exceed $4.29 as expected?
A strong EPS could reinforce investor confidence in Vertex's profitability and growth potential.
Q2
What guidance will management provide for future revenue?
Guidance on revenue will be crucial for assessing the company's growth trajectory and market position.
—
Est. EPS
$0.01
Est. Rev
$918M
Impl. Move
±9.1%
Why consensus could be wrong
The Street may be underestimating the potential for Vertex to exceed its earnings expectations due to strong sales in its existing therapies.
Supporting evidence
Vertex has consistently beaten EPS estimates in recent quarters, suggesting a trend of strong performance.
The options market is pricing a 6.07% move, indicating expectations for volatility that may not align with the company's historical stability.
Key risk
If revenue growth exceeds $3.2 billion, it could challenge the current consensus and shift investor sentiment positively.
Pre-commit to what would confirm each case.
The market is debating Vertex's ability to maintain its growth momentum amidst competitive pressures and market dynamics.
Bull confirmed if
An EPS of $4.50 or higher would confirm the bull case by showcasing strong earnings growth.
Bear confirmed if
An EPS below $4.00 would confirm the bear case, indicating potential issues in performance.
What the market is pricing for the move.
Implied Move
±6.07%
Historical Avg
±0.8%
The options market is pricing in a significant move, indicating that investors expect volatility around the earnings report.
Options are pricing ±6.1% while VRTX has averaged ±0.8% over the last 8 prints — setup is pricing rich.
ATM IV
0.6%
30d HV
23.2%
Smart-money positioning from the most recent 13F filings.
Institutional
97.99%
of float
Insider
0.21%
of float
Holders
2,428
institutions
Top Holders· as of Jun 2026
Capital World Investors
26,115,014 sh · $13.2B
10.29%
2.9%
Likely market behavior by outcome. Not investment advice.
Beat & raise
If Vertex beats expectations, history suggests the stock could rise by around 0.54%, confirming strong demand for its products.
In line / cautious
If results are in line with expectations, the stock may experience muted movement as investors await further clarity from management.
Miss
If Vertex misses expectations, history suggests a potential decline of around 2.03%, raising concerns about future growth.
House and Senate STOCK Act disclosures over the trailing 6 months.
Trades
1
0 buys·1 sell
Members
1
House only
Est. Notional
$1,001.00–$15,000.00
disclosed dollar ranges
Most Active Members
1 trade
The lines on the call that would change the story.
Blackrock Inc.
24,109,373 sh · $12.2B
9.50%
0.6%
Capital Research Global Investors
19,490,637 sh · $9.9B
7.68%
-7.7%
Vanguard Capital Management LLC
16,580,713 sh · $8.4B
6.53%
0.4%
State Street Corporation
11,871,459 sh · $6.0B
4.68%
1.2%
13F filings updated quarterly. Position deltas show change in shares vs. the prior quarter.
Net selling
Recent Transactions
Traded Aug 26, 2026 · disclosed Sep 5, 2026
$1,001.00–$15,000.00
Filed 30–45+ days after the trade. Treat as positional context, not a leading indicator. Amounts are SEC-mandated dollar ranges, not exact values.